deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT02555683

Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.

Sponsor: Novartis Pharmaceuticals

Conditions Asthma
Interventions Placebo QAW039
Updated 17 times since 2017 Last updated: May 4, 2020 Started: Dec 11, 2015 Primary completion: Oct 21, 2019 Completion: Nov 4, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Asthma, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 17 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Mar 2018 · 10 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Feb 2019 · 3 months · monthly snapshot~Feb 2019 – ~Jul 2019 · 5 months · monthly snapshot~Jul 2019 – ~Nov 2019 · 4 months · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~Jun 2020 · 5 months · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 4 months · monthly snapshot

Change History

17 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Feb 2026 [monthly]

    Completed PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 12 earlier versions

  1. Jun 2020 — Jan 2021 [monthly]

    Completed PHASE3

  2. Jan 2020 — Jun 2020 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  3. Nov 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE3

  4. Jul 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE3

  5. Feb 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  6. Nov 2018 — Feb 2019 [monthly]

    Recruiting PHASE3

  7. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  8. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  9. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  10. May 2017 — Mar 2018 [monthly]

    Recruiting PHASE3

  11. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE3

  12. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalst, Belgium , Amstetten, Austria , Arad, Romania , Bangor, United States , Barcelona, Spain , Basel, Switzerland , Bedford Park, Australia , Beijing, China , Bellevue, United States , Berlin, Germany and 179 more locations